What is Gufic Biosciences Ltd (GUFICBIO) share price return in the past 10 years?

Gufic Biosciences Ltd share price has appreciated 24.5% annually (CAGR) over the past ten years.

What is the share price of Gufic Biosciences Ltd (GUFICBIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Gufic Biosciences Ltd (GUFICBIO) on 05-Jun-2026 16:59:59 at 16:59 is 369.55.

What is the P/E ratio of Gufic Biosciences?

The latest standalone P/E ratio of Gufic Biosciences as of 05-Jun-2026 is 56.62.

What is the P/B ratio of Gufic Biosciences Ltd (GUFICBIO)?

The latest standalone P/B ratio of Gufic Biosciences Ltd (GUFICBIO) as of 05-Jun-2026 is 5.38.

What is the 52-week high and low of Gufic Biosciences Ltd (GUFICBIO)?

The 52-week high of Gufic Biosciences Ltd (GUFICBIO) is Rs. 409.00 and the 52-week low is Rs. 267.50.

Gufic Biosciences Ltd (GUFICBIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Gufic Biosciences Ltd (GUFICBIO)
Brand: Gufic Biosciences

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

Gufic Biosciences Ltd (GUFICBIO)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 509079 NSE: GUFICBIO Pharmaceuticals & Drugs | Small Cap | Gufic Biosciences Share Price

Key Metrics

Valuation Multiples

Market Cap

₹3,576 Cr.

Current Price

₹369.6

52-Week Low / High

₹268 / 409

TTM EPS

₹6.3

TTM Sales

₹940 Cr.

Book Value per Share

₹66.2

P/E Ratio

56.62

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

5.38

Lower than its 5-year historical median

Price to Sales (P/S)

3.80

Higher than its 5-year historical median

EV/EBITDA

25.41

Higher than its 5-year historical median

Dividend Yield

0.03%

Profitability Efficiency

Return on Equity (ROE)

12.34%

Outperforms industry median

Return on Capital Employed (ROCE)

13.51%

Outperforms industry median

Return on Assets (ROA)

6.18%

Operating Profit Margin

16.9%

Net Profit Margin

8.53%

Gross Profit Margin

10.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

1.63%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-7.4%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-18.82%

Asset Quality

Promoter Holding

72.50%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹654 Cr.

Equity

₹10 Cr.

Face Value

₹1

All Time Low / High

₹0.17 / 501.10

Gufic Biosciences stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Fair

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Gufic Biosciences Ltd a good quality company?

Gufic Biosciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Gufic Biosciences Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Gufic Biosciences Ltd vs industry peers?

Gufic Biosciences Ltd revenue CAGR is 16.69%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Gufic Biosciences Ltd?

Promoters hold 72.50% of the Gufic Biosciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Gufic Biosciences Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 21.8% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	24.2%	24.3%	34.1%	29.7%	21%	30.1%	47.3%	23.2%	17.6%	13.5%	-
Value Creation Index ⓘ	0.7	0.7	1.4	1.1	0.5	1.2	2.4	0.7	0.3	0.0	-
Growth Parameters ⓘ
Sales ⓘ	202	246	306	351	379	488	779	691	807	820	940
Sales YoY Gr.	-	21.4%	24.5%	14.8%	8%	28.7%	59.8%	-11.4%	16.8%	1.6%	-
Adj EPS ⓘ	1	1.1	1.9	2.8	2.4	4.5	9.8	8.4	8.7	7.1	6.3
YoY Gr.	-	12.1%	74.8%	43.3%	-15.1%	89%	120.4%	-14.2%	3.4%	-18.2%	-
BVPS (₹) ⓘ	4.4	4.8	7	9.7	13.3	17.9	27.8	35.9	53.1	60	66.2
Adj Net Profit ⓘ	7.6	8.6	15.1	21.7	22.9	43.2	95.3	81.8	87.4	71.5	63
Cash Flow from Ops. ⓘ	-4.3	-4.1	-4.8	5.2	47.1	87.3	106	-26.6	-7.5	123	-
Debt/CF from Ops. ⓘ	-9.9	-13.7	-16.5	18.8	2.5	0.6	0.6	-11.7	-42.5	2.5	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	16.8%	16.7%	1.7%	1.6%
Adj EPS ⓘ	24.5%	24.8%	-10.2%	-18.2%
BVPSⓘ	33.7%	35.1%	29.3%	12.9%
Share Price	24.5%	14.2%	23.6%	0.7%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	25	24.2	33	33.5	22.3	28.5	43.1	26.5	19.9	12.6	10
Op. Profit Mgn % ⓘ	10	9.4	12.7	13.1	13.8	17.2	19	19.9	18.6	16.9	16
Net Profit Mgn % ⓘ	3.8	3.5	4.9	6.2	6	8.9	12.2	11.8	10.8	8.7	6.7
Debt to Equity ⓘ	1.3	1.5	1.5	1.3	0.9	0.3	0.2	0.9	0.6	0.5	0.2
Working Cap Days ⓘ	187	190	201	239	254	201	136	187	213	203	142
Cash Conv. Cycle ⓘ	40	67	86	73	84	47	31	55	91	83	50

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	202	246	306	351	379	488	779	691	807	820
Operating Expenses ⓘ +	183	223	267	305	327	404	631	556	659	683
Manufacturing Costs	27	32	41	47	51	57	93	87	107	125
Material Costs	91	107	129	161	156	226	368	295	339	310
Employee Cost	32	41	45	47	59	66	86	87	110	127
Other Costs ⓘ	33	42	52	50	60	55	84	86	103	121
Operating Profit ⓘ	20	23	39	46	52	84	148	135	147	136
Operating Profit Margin (%)	9.7%	9.3%	12.7%	13.1%	13.8%	17.2%	19.0%	19.5%	18.3%	16.6%
Other Income ⓘ +	1	1	3	4	6	4	3	3	2	4
Exceptional Items ⓘ	0	0	2	0	0	0	0	0	0	0
Interest ⓘ	6	6	9	10	14	14	5	8	17	25
Depreciation ⓘ	4	4	4	5	14	16	19	22	17	21
Profit Before Tax ⓘ	10	14	30	35	30	58	127	107	116	94
Tax ⓘ	3	5	13	13	7	13	31	27	30	24
Profit After Tax	7	9	16	22	23	44	96	80	86	70
PAT Margin (%)	3.6%	3.7%	5.4%	6.3%	6.0%	9.1%	12.3%	11.5%	10.7%	8.5%
Adjusted EPS (₹)	1.0	1.2	2.1	2.8	2.3	4.6	9.9	8.2	8.6	7.0
Dividend Payout Ratio (%)	5.30%	4.30%	2.40%	1.80%	2.10%	2.20%	1%	1.20%	1.20%	1.40%

Valuation of Gufic Biosciences - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	34	37	54	75	129	173	269	348	533	601
Share Capital ⓘ	8	8	8	8	10	10	10	10	10	10
Reserves ⓘ	26	30	46	68	120	164	259	338	523	591
Debt +	40	54	77	96	113	52	55	302	296	285
Long Term Debt	8	7	8	11	20	35	48	191	154	130
Short Term Debt	32	47	69	85	93	16	7	112	142	154
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	53	44	76	78	117	111	141	130	166	159
Others Liabilities ⓘ	26	40	28	61	48	83	57	80	98	125
Total Liabilities ⓘ	152	175	235	310	407	419	521	860	1,093	1,170
Fixed Assets
Net Fixed Assets ⓘ +	22	22	23	24	83	100	115	160	159	506
Gross Block	51	26	31	37	115	149	180	246	246	614
Accumulated Depreciation	29	4	8	13	32	49	64	87	87	108
CWIP ⓘ	0	0	2	10	31	13	41	170	307	22
Investments ⓘ	0	0	0	0	0	0	0	1	2	3
Inventories	50	63	94	94	122	94	116	183	200	217
Trade Receivables	56	52	81	103	107	125	152	205	330	315
Cash Equivalents	6	6	7	8	16	13	27	47	13	28
Others Assets ⓘ	17	32	28	71	48	74	72	95	81	79
Total Assets ⓘ	152	175	235	310	407	419	521	860	1,093	1,170

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-4	-4	-5	5	47	87	106	-27	-7	123
PBT ⓘ	11	14	30	35	30	58	127	107	116	94
Adjustment ⓘ	9	10	12	13	25	31	23	30	34	44
Changes in Working Capital ⓘ	-21	-24	-30	-34	2	8	-11	-135	-130	7
Tax Paid ⓘ	-3	-5	-16	-10	-10	-9	-33	-28	-27	-23
Cash Flow From Investing Activity ⓘ +	-1	-5	-9	-13	-43	-7	-95	-191	-102	-72
Capex	-1	-4	-8	-13	-40	-12	-87	-188	-108	-71
Net Investments	0	0	0	0	0	0	0	-1	-1	-1
Others ⓘ	0	-1	-1	0	-3	6	-7	-2	7	-0
Cash Flow From Financing Activity ⓘ +	5	7	14	8	-4	-79	-6	234	82	-37
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	100	0
Net Proceeds from Borrowing ⓘ	-4	-1	1	3	7	12	12	107	-37	-24
Interest Paid ⓘ	-5	-6	-8	-10	-14	-13	-5	-8	-13	-21
Dividend Paid ⓘ	-0	-0	-0	-0	-0	-0	-1	-1	-1	-1
Others ⓘ	14	15	22	15	3	-77	-12	136	33	8
Net Cash Flow ⓘ	-0	-1	1	-0	0	2	5	17	-27	14

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	23.99	25.31	36.03	33.89	22.17	29.22	43.31	25.84	19.57	12.34
ROCE (%)	24.24	24.26	34.1	29.65	21.01	30.05	47.29	23.23	17.56	13.51
Asset Turnover Ratio	1.53	1.59	1.55	1.32	1.09	1.26	1.8	1.16	0.96	0.97
PAT to CFO Conversion(x)	-0.57	-0.44	-0.31	0.23	2.04	1.98	1.1	-0.34	-0.08	1.76
Working Capital Days
Receivable Days	76.40	75.90	76.40	93.20	98	81.40	59.40	81.40	103.90	106.90
Inventory Days	74.20	79.40	90.40	95.40	101.10	76.30	45.20	68.10	74.50	69.20
Payable Days	205.20	163.70	169.90	173.90	227.30	184.30	124.90	167.50	159.60	191.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

The current trading price of Gufic Biosciences on 05-Jun-2026 16:59 is ₹369.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Gufic Biosciences stood at ₹3,575.6 Cr

The latest P/E ratio of Gufic Biosciences as of 04-Jun-2026 is 56.62.

The latest P/B ratio of Gufic Biosciences as of 04-Jun-2026 is 5.38.

The 52-week high of Gufic Biosciences is ₹409.0 and the 52-week low is ₹267.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹940 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a average quality company.

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

Pharmaceutical
Herbal
API / Bulk Drugs
Personal care
International

History and milestone

Past Initiatives

First Indian to produce Doxycycline Inj.
First Indian company to make Liquid Oxytetracycline Inj.
Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
First Company to launch Boswellia Serrata tablets
Pioneer in developing Kid tablet in India
Hived off Mox and Zole to Ranbaxy

2007-2009

Initiated contract manufacturing
Commenced international exports

2010-2015

Received patents for Anidulafungin and Tigecycline lyophilized inj.
Launched Criticare division

2016

Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
Launched Ferticare and Criticare Life divisions

2017-2019

Received patents for Rifabutin and Micafunginlyophilized inj.
Exported Vancomycin lyophilized Inj. to Germany
Manufacturing capacity ramped up to 31 million vials per annum
Launched Ferticare Life division

2020

Manufacturing Remdesivir for Hetero
Increased capacity to 48 million vials per annum

2022

Incorporated wholly owned subsidiary company namely ‘Gufic UK’
Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)

Gufic Biosciences Ltd (GUFICBIO)

Gufic Biosciences Ltd (GUFICBIO)

Gufic Biosciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Gufic Biosciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

About Gufic Biosciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Gufic Biosciences Ltd (GUFICBIO)

Gufic Biosciences Ltd (GUFICBIO)

Gufic Biosciences stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Gufic Biosciences - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gufic Biosciences Ltd FAQs

What is the share price of Gufic Biosciences?

What is the market cap of Gufic Biosciences?

What is the P/E ratio of Gufic Biosciences?

What is the P/B ratio of Gufic Biosciences?

What is the 52-week high and low of Gufic Biosciences?

What is the TTM revenue of Gufic Biosciences?

Is Gufic Biosciences Ltd a good quality company?

Is Gufic Biosciences Ltd undervalued or overvalued?

Is Gufic Biosciences Ltd a good buy now?

About Gufic Biosciences Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.